BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 28457113)

  • 1. Stereotactic Ablative Body Radiation for Stage I Lung Cancer in Israel: A Retrospective Single-Center Report.
    Appel S; Lawrence YR; Goldstein J; Pfeffer RM; Weiss I; Rabin T; Felder S; Ben-Ayun M; Tzvang L; Alezra D; Simansky D; Ben-Nun A; Bar J; Symon Z
    Isr Med Assoc J; 2017 Jan; 19(1):39-43. PubMed ID: 28457113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
    Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
    Radiother Oncol; 2021 Mar; 156():153-159. PubMed ID: 33333139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.
    Kelley KD; Benninghoff DL; Stein JS; Li JZ; Byrnes RT; Potters L; Knisely JP; Zinkin HD
    Radiat Oncol; 2015 May; 10():120. PubMed ID: 26018408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
    Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic Ablative Radiation Therapy for Large (≥5 cm) Non-small Cell Lung Carcinoma.
    McDermott RL; Mihai A; Dunne M; Keys M; O'Sullivan S; Thirion P; ElBeltagi N; Armstrong JG
    Clin Oncol (R Coll Radiol); 2021 May; 33(5):292-299. PubMed ID: 33309479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Overall Survival Outcomes in Patients with Early Stage, Peripherally Located, Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy in a Non-academic Cancer Centre.
    Wood A; Aynsley E; Kumar G; Masinghe S; Anderson M; Veeratterapillay J; Huntley C; Blower A; Green J; Johnson D; Daniel J; Curtis H; Reynolds J; Turnbull M; Harland K; Swingler A; Banham E; Burke K; Bradley J; Greenhalgh A; Peedell C
    Clin Oncol (R Coll Radiol); 2021 May; 33(5):283-291. PubMed ID: 33341333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and risk factors for chest wall toxicity after risk-adapted stereotactic radiotherapy for early-stage lung cancer.
    Bongers EM; Haasbeek CJ; Lagerwaard FJ; Slotman BJ; Senan S
    J Thorac Oncol; 2011 Dec; 6(12):2052-7. PubMed ID: 22052227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.
    Bhandari RP; Stanford JD; Packianathan S; Duggar WN; Kanakamedala MR; Zhang X; Giri SP; Kumar PP; Harrell LM; Mangana SH; Yang C; Vijayakumar S
    Oncology; 2016; 91(4):194-204. PubMed ID: 27427761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
    Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors in medically inoperable early stage lung cancer patients treated with stereotactic ablative radiation therapy (SABR): Turkish Radiation Oncology Society Multicentric Study.
    Sahin B; Atalar B; Kaytan Saglam E; Akgun Z; Abacioglu U; Arifoglu A; Ozyar E; Yaprak G; Ozseker Isik N; Guney Y; Caglar HB; Karaman S; Igdem S; Selek U; Berber T; Oner Dincbas F; Sengoz M; Yucel S; Demiral AN; Akyurek S
    Clin Respir J; 2020 Nov; 14(11):1050-1059. PubMed ID: 32749053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
    Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
    Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic Ablative Radiotherapy (SABR) in Patients with Medically Inoperable Peripheral Early Stage Lung Cancer: Outcomes for the First UK SABR Cohort.
    Murray L; Ramasamy S; Lilley J; Snee M; Clarke K; Musunuru HB; Needham A; Turner R; Sangha V; Flatley M; Franks K
    Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):4-12. PubMed ID: 26474546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical prognostic factors and grading system for rib fracture following stereotactic body radiation therapy (SBRT) in patients with peripheral lung tumors.
    Kim SS; Song SY; Kwak J; Ahn SD; Kim JH; Lee JS; Kim WS; Kim SW; Choi EK
    Lung Cancer; 2013 Feb; 79(2):161-6. PubMed ID: 23182662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
    Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
    Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of chest wall toxicity after stereotactic ablative radiotherapy using real-time tumor tracking for lung tumors.
    Park Y; Kim HJ; Chang AR
    Radiat Oncol; 2017 Apr; 12(1):66. PubMed ID: 28381302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung stereotactic ablative radiotherapy (SABR): dosimetric considerations for chest wall toxicity.
    Murray L; Karakaya E; Hinsley S; Naisbitt M; Lilley J; Snee M; Clarke K; Musunuru HB; Ramasamy S; Turner R; Franks K
    Br J Radiol; 2016; 89(1058):20150628. PubMed ID: 26760508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer.
    Haasbeek CJ; Lagerwaard FJ; Slotman BJ; Senan S
    J Thorac Oncol; 2011 Dec; 6(12):2036-43. PubMed ID: 21892102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic ablative body radiation therapy for tumors in the lung in octogenarians: a retrospective single institution study.
    Cannon NA; Iyengar P; Choy H; Timmerman R; Meyer J
    BMC Cancer; 2014 Dec; 14():971. PubMed ID: 25518879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors.
    Chaudhuri AA; Tang C; Binkley MS; Jin M; Wynne JF; von Eyben R; Hara WY; Trakul N; Loo BW; Diehn M
    Lung Cancer; 2015 Jul; 89(1):50-6. PubMed ID: 25997421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.